• Home
  • Biopharma AI
  • How Xsolis’ AI-Driven Dragonfly Clinched the 2025 MedTech’s ‘Clinical Efficiency Innovation Award’? Targets the $1 Trillion U.S. Healthcare Waste Crisis Clinical Efficiency Innovation Award

How Xsolis’ AI-Driven Dragonfly Clinched the 2025 MedTech’s ‘Clinical Efficiency Innovation Award’? Targets the $1 Trillion U.S. Healthcare Waste Crisis Clinical Efficiency Innovation Award

Key Highlights

  • Xsolis’ Dragonfly awarded 2025 MedTech Breakthrough “Clinical Efficiency Innovation Award” for transforming payer-provider collaboration using AI
  • Dragonfly leverages real-time predictive analytics to optimize care levels, reduce waste, and streamline medical necessity decisions
  • Generative AI integration positions Dragonfly as a next-gen digital co-pilot for nurses, providers, and payers across the U.S.

Xsolis Sets New Standard in AI-Powered Clinical Efficiency
Tennessee-based AI tech firm Xsolis has won top honors at the 2025 MedTech Breakthrough Awards for its Dragonfly platform, recognized as a market leader in solving one of healthcare’s most expensive and complex challenges: administrative waste. Dragonfly uses predictive analytics to assign objective medical necessity scores and suggest care levels in real time, aligning health plans and providers before conflict arises.

Dragonfly: Turning Friction into Function Between Payers and Providers
Administrative overhead in U.S. healthcare approaches $1 trillion annually—primarily due to inefficient workflows between insurers and providers. Dragonfly addresses this by integrating directly into hospital systems, automatically generating aligned medical necessity decisions. The platform removes guesswork and redundancy while enabling shared data access across previously siloed stakeholders.

Generative + Predictive AI: A Digital Co-Pilot for Clinicians
Launched in late 2024, Dragonfly’s latest upgrade adds generative AI to its predictive core. Nurses and care managers benefit from decision support that eliminates repetitive tasks, reduces documentation burden, and boosts accuracy in level-of-care forecasting. It enables smarter, more collaborative care transitions—improving patient outcomes while protecting clinicians’ time.

Market Impact: Global Recognition for U.S. Innovation
The 2025 MedTech Breakthrough Awards received record-breaking entries from over 18 countries. Xsolis’ win validates its growing influence as an AI innovator redefining value-based care infrastructure. With payer-provider friction identified as the top barrier in a 2024 HFMA survey of revenue leaders, Dragonfly is positioned as a must-have solution for sustainable digital healthcare delivery.

About Xsolis
Xsolis is a Franklin, Tennessee-based AI healthcare technology company helping providers and payers reduce friction, align on medical necessity, and eliminate administrative waste through predictive analytics. Its flagship solution, Dragonfly®, offers a real-time, interoperable platform that enables smarter utilization decisions and better patient care outcomes.

About MedTech Breakthrough
MedTech Breakthrough is part of Tech Breakthrough, a leading market recognition platform honoring excellence in digital health and medical technologies. Its annual awards spotlight disruptive innovators across categories such as patient engagement, AI, cybersecurity, and clinical operations.

Releated Posts

Can Sanofi SA’s New AI-Enabled Innovation Hub in China Accelerate Global Drug Development and Reshape Biopharma Operations Across Asia?

Key Highlights: AI-Integrated Innovation Hubs Redefine Global R&D ModelsSanofi SA’s launch of its innovation and operations centre in…

ByByAnuja Singh Mar 24, 2026

Strategic Industry Release: How AI Companies Led Biopharma Innovation Through Major Collaborations in 2025

Artificial intelligence companies emerged as critical innovation partners for the global biopharmaceutical industry in 2025, reshaping how drugs…

ByByAnuja Singh Mar 6, 2026

AI in Life Sciences: A Multi-Billion Dollar Transformation Reshaping Drug Discovery and Healthcare

Artificial intelligence is rapidly becoming one of the most transformative forces in the life sciences industry. Global investment…

ByByAnuja Singh Mar 6, 2026

How Does Eli Lilly Secure $100B+ Obesity Dominance Through 8 Triple/Triple+ Agonist Launches by 2030?

Eli Lilly establishes unrivaled obesity leadership through its 40 Phase 2/3 programs and 34 discovery-stage assets, commanding 60% US GLP-1 market share via Mounjaro/Zepbound ($39.5B 2025 revenue)…

ByByAnuja Singh Mar 5, 2026
Scroll to Top